Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).
WuXi TIDES boosts oligo, peptide offerings due to a rise in demand, with three new builds ongoing
BARCELONA — Oligonucleotide and peptide provider WuXi TIDES is increasing its service capacity due to a rise in customers, particularly from biopharma companies that have
October 27, 2023